629 Comparison of lower urinary tract symptoms and sexual function response to convective radiofrequency thermal therapy of prostate (Rezûm®) to MTOPS study cohort

Medical therapy is commonly used to treat lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), but can negatively impact sexual function. Rezum (REZ), a convective radiofrequency thermal therapy, shows promising results for LUTS/BPH. We report the effect of REZ on LUTS and sexual function compared to the Medical Therapy of Prostatic Symptoms (MTOPS) study historical cohort. Results from the treatment arm of a double-blinded, randomized, controlled trial of REZ were compared to results of the MTOPS therapy arms, doxazosin (DOX), finasteride (FIN), or combination of both (COM) in subjects with prostate volumes ≥ 30cc and IPSS ≥ 13. IPSS, BPH Impact Index (BPHII), peak flow rate (Qmax), PVR, erectile and ejaculatory function were compared at 3, 6, 12, and 24 months. Propensity score weighting was performed to eliminate differences in IPSS, QOL and prostate volume between groups at baseline; outcomes were assessed at 3, 6, 12, and 24 months.